Emcure Receives CDSCO Nod to Expand Poviztra's Use for MASH Indication
Emcure has received CDSCO approval to expand Poviztra's use for non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH), addressing a major unmet need in progressive liver disease treatment.
MASH Treatment India | 21/07/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy